Er aggravated by ROS and hypoxia (Fig. 5B). The role of TUSC2 as a tumor suppressor in lung cancer is widely accepted [16-18]. TUSC2 delivered in lipid-based nanoparticles drastically reduced the number and size of human non-small cell lung cancer tumors in mice [19]. The TUSC2 nanoparticles are being tested in a phase 1 safety and dose-escalation clinical trial at the M. D. Anderson Cancer Center